Plasma Hepcidin as a potential informative biomarker of Alzheimer disease and vascular dementia.

ABSTRACT:

Background

Blood-based assays are expected to be integrated into clinical routines across various contexts, including Alzheimer's disease (AD). Vascular dementia (VaD), which is the second most common cause leading to dementia after AD, could also significantly benefit from this advancement. However, no informative fluid biomarker has been identified for VaD. Given the disruption of iron homeostasis in both AD and VaD, this study aims to characterize the potential of the iron-related hormone Hepcidin as a biomarker for these two conditions. We will compare its added value to established AT(N) blood biomarkers.

Methods

Blood biomarkers (amyloid-composite, p-Tau₁₈₁, Neurofilament Light Chain [NfL] and Hepcidin) levels in blood were analyzed in two independent cohort

SUBMITTER: Delaby C 

PROVIDER: S-EPMC11823057 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature